These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33809064)

  • 1. A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma.
    Fawwaz M; Mishiro K; Nishii R; Makino A; Kiyono Y; Shiba K; Kinuya S; Ogawa K
    Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33809064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
    Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Makino A; Miyazaki A; Tomoike A; Kimura H; Arimitsu K; Hirata M; Ohmomo Y; Nishii R; Okazawa H; Kiyono Y; Ono M; Saji H
    Bioorg Med Chem; 2018 May; 26(8):1609-1613. PubMed ID: 29478801
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Kimura H; Okuda H; Ishiguro M; Arimitsu K; Makino A; Nishii R; Miyazaki A; Yagi Y; Watanabe H; Kawasaki I; Ono M; Saji H
    ACS Med Chem Lett; 2017 Apr; 8(4):418-422. PubMed ID: 28435529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and initial
    Fawwaz M; Mishiro K; Arwansyah A; Nishii R; Ogawa K
    Bioimpacts; 2024; 14(1):27774. PubMed ID: 38327635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
    Nishiya N; Sakamoto Y; Oku Y; Nonaka T; Uehara Y
    World J Biol Chem; 2015 Nov; 6(4):409-18. PubMed ID: 26629323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines].
    Li J; Wu X; Wang Z; Shen Z; Sun N; Zhu X
    Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):475-80. PubMed ID: 26302343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer.
    Sun P; Qu Y; Wang Y; Wang J; Wang X; Sheng J
    J Cancer; 2021; 12(13):3900-3908. PubMed ID: 34093797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
    Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
    Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound 15c, a Novel Dual Inhibitor of EGFR
    Chen G; Bao Y; Weng Q; Zhao Y; Lu X; Fu L; Chen L; Liu Z; Zhang X; Liang G
    Front Pharmacol; 2019; 10():1533. PubMed ID: 31998131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET.
    Abourbeh G; Itamar B; Salnikov O; Beltsov S; Mishani E
    EJNMMI Res; 2015; 5():4. PubMed ID: 25853010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis.
    Chen LY; Molina-Vila MA; Ruan SY; Su KY; Liao WY; Yu KL; Ho CC; Shih JY; Yu CJ; Yang JC; Rosell R; Yang PC
    Lung Cancer; 2016 Apr; 94():46-53. PubMed ID: 26973206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis.
    Liang H; Pan Z; Wang W; Guo C; Chen D; Zhang J; Zhang Y; Tang S; He J; Liang W;
    J Thorac Dis; 2018 Apr; 10(4):2311-2320. PubMed ID: 29850136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
    Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
    Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing Non-Nucleosidic Reverse Transcriptase Inhibitors (NNRTIs) to Overcome EGFR T790M-Mediated Acquired Resistance in Non-Small Cell Lung Cancer.
    Ahmad I; Patel HM
    J Cell Biochem; 2024 Sep; ():e30653. PubMed ID: 39300843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EGFR
    Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
    Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 99mTc-HYNIC-MPG as a novel SPECT radiotracer to detect EGFR-activating mutations in NSCLC.
    Xiao Z; Song Y; Kai W; Sun X; Shen B
    Oncotarget; 2017 Jun; 8(25):40732-40740. PubMed ID: 28489575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.